The lawsuit claims that Hims & Hers failed to disclose that it shared sensitive consumer health information with third-party advertising platforms. Furthermore, the complaint alleges the company misrepresented its medical consultation process, specifically charging customers for prescriptions immediately after intake forms were submitted, despite suggesting that providers would first determine if a treatment was appropriate for the user. These practices reportedly invited heightened regulatory scrutiny and the risk of significant financial penalties, which the firm allegedly concealed from the market.

Rosen Law Firm, which represents the class, argues that these omissions rendered the company's public statements about its business health materially misleading. Investors who suffered losses during the specified period may join the action without out-of-pocket costs through a contingency fee arrangement. While the firm encourages investors to seek qualified legal representation, it notes that no class has been certified yet. Shareholders retain the right to select their own counsel, remain absent from the litigation, or seek appointment as lead plaintiff before the November deadline.